Swi5 is a physiological substrate of the SCFCdc4 complex. (A and B) Swi5 is stabilized and accumulates in nuclei of cells with functionally defective SCFCdc4 complex. Log phase cultures of TK769 (GAL-CDC20 SWI5-Myc) and TK770 (GAL-CDC20 SWI5-Myc cdc4–1) were arrested in metaphase in YPR medium. Cells were released from the metaphase arrest by the addition of galactose and further cultured at 30°C (TK769) or 37°C (TK770). Aliquots were taken at 20 min intervals for protein analysis (A) and for determination of subcellular localization (B). (A) Protein levels of Swi5-Myc, Clb2, and Cdc28 were analyzed by immunoblotting. (B) Swi5-Myc was visualized by anti-Myc antibody (9E10). DAPI (4′6-diamidino-2-phenylindole) was used to visualize nuclei. Numbers in parentheses represent the numbers of strains. (C) Swi5-ST8A-HH is stabilized in vivo. Cultures of TK713 (GAL-CDC20 SWI5-HH) or TK-714 (GAL-CDC20 SWI5-ST8A-HH) cells were processed as described in Fig. 2a at 30°C. Aliquots were taken at the time indicated and immunoblotted. (D) Cells arrested at G1 phase by α factor were treated with galactose for 20 min (to induce expression of Swi5-Myc or Swi5-ST8A-Myc) and then with cycloheximide. Aliquots were taken at the preselected time, and degradation of Swi5-Myc or Swi5-ST8A-Myc was monitored by immunoblotting. Bands were quantified, and Swi5-Myc signals were normalized against Cdc28 signals from the same blot probed with anti-PSTAIRE antibody. Values are shown as a percentage of the signal at 0 min time point: Swi5-Myc in wild-type cells (○) or in srb10Δ mutants (●); Swi5-ST8A-Myc in wild-type cells (□) or in srb10Δ mutants (■). (E) Ubiquitination of Swi5 in vivo. (Top) pdr5Δ mutants (lanes 1–10) or cdc4–1 pdr5Δ mutants (lanes 11 and 12) in the absence (lanes 1, 3, 5, 7, 9, and 11) or presence (lanes 2, 4, 6, 8, 10, and 12) of MG132, with the use of the following combinations of plasmids: YC33G (control plasmid) and pCUP-UbiHIS-MYC-RA (lanes 1 and 2); YC33G-SWI5-HA and pCUP-UbiHIS-MYC-RA (lanes 3, 4, 9, and 10); YC33G-SWI5-HA and pCUP-UbiMYC-RA (lanes 5 and 6); YC33G-SWI5-ST8A-HA and pCUP-UbiHIS-MYC-RA (lanes 7 and 8); and pYES2-SWI5-HA and pCUP-UbiHIS-MYC-RA (lanes 11 and 12). We used pYES2-SWI5-HA (a high-copy plasmid for expression of SWI5-HA from GAL1 promoter) because expression of Swi5-HA from YC33G-SWI5-HA was low in cdc4–1 pdr5Δ mutants. Extracts were incubated with Ni-NTA beads, and bead-bound proteins were immunoblotted with anti-HA (12CA5) antibody. (*, Nonspecific signals detected in this experiment.) (Middle and Bottom) Total extracts were analyzed by immunoblotting to examine the expression of Swi5-HA (Middle) and Cdc28 as loading control (Bottom).